$39.25
0.36% day before yesterday
Nasdaq, Dec 24, 10:38 pm CET
ISIN
GB00BMVP7Y09
Symbol
RPRX

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$39.25
-0.50 1.26% 1M
+3.11 8.61% 6M
+13.74 53.86% YTD
+14.02 55.57% 1Y
-0.19 0.48% 3Y
-9.65 19.73% 5Y
-5.25 11.80% 10Y
-5.25 11.80% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.14 0.36%
ISIN
GB00BMVP7Y09
Symbol
RPRX
Industry

New AI Insights on Royalty Pharma plc - Ordinary Shares - Class A Insights AI Insights on Royalty Pharma plc - Ordinary Shares - Class A

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$22.7b
Enterprise Value
$29.8b
Net debt
$7.1b
Cash
$1.8b
Shares outstanding
579.0m
Valuation (TTM | estimate)
P/E
28.9 | 8.2
P/S
9.6 | 7.3
EV/Sales
12.7 | 9.6
EV/FCF
31.5
P/B
3.5
Dividends
DPS
$0.88
Yield 1Y | 5Y
2.2% | 2.2%
Growth 1Y | 5Y
4.8% | 24.0%
Payout 1Y | 3Y
58.3% | 70.2%
Increased
6 Years
Financials (TTM | estimate)
Revenue
$2.3b | $3.1b
EBITDA
- | $2.9b
EBIT
$1.5b | $2.8b
Net Income
$765.0m | $2.8b
Free Cash Flow
$944.7m
Growth (TTM | estimate)
Revenue
3.7% | 37.7%
EBITDA
- | 127.6%
EBIT
-0.7% | 114.8%
Net Income
-33.2% | 224.2%
Free Cash Flow
544.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | 94.4%
EBIT
65.2%
Net
32.6% | 89.4%
Free Cash Flow
40.2%
Financial Health
Equity Ratio
38.1%
Return on Equity
12.4%
ROCE
8.2%
ROIC
8.8%
Debt/Equity
1.4
More
EPS
$1.4
FCF per Share
$1.6
Short interest
6.6%
Employees
-
Rev per Employee
-
Show more

Is Royalty Pharma plc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy
80%
Hold
20%

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,350 2,350
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 570 570
150% 150%
24%
- Research and Development Expense 402 402
20,000% 20,000%
17%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,533 1,533
1% 1%
65%
Net Profit 765 765
33% 33%
33%

In millions USD.

Don't miss a Thing! We will send you all news about Royalty Pharma plc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
10 days ago
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.
Neutral
GlobeNewsWire
22 days ago
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Neutral
GlobeNewsWire
22 days ago
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office United Kingdom
CEO Pablo Legorreta
Founded 1996
Website www.royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today